To present an overview of the company's growth strategy, current products and pipelines, and business outlook

Par Pharmaceutical Companies Inc. announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for the 100mg and 200mg strengths of tramadol ER. Ortho-McNeil sells extended-release tramadol tablets under the brand name Ultram® ER. Par has been awarded 180 days of marketing exclusivity, commencing at launch, for being the first to file an ANDA containing a paragraph IV certification for the product. Annual U.S. sales of the 100mg and 200mg strengths of Ultram® ER are approximately $156 million, according to IMS Health data. Par began shipping tramadol ER to the trade upon approval.

Par Pharmaceutical Companies Inc. announced unaudited consolidated financial results for the third quarter and nine months ended October 3, 2009. For the quarter, the company reported total revenues of $294,802,000, operating income of $42,377,000, income from continuing operations before provision for income taxes of $42,723,000, income from continuing operations of $26,514,000 or $0.77 per diluted share, net income of $26,338,000 or $0.76 per diluted share against total revenues of $148,967,000, operating income of $4,622,000, income from continuing operations before provision for income taxes of $821,000, income from continuing operations of $625,000 or $0.01 per diluted share, net income of $475,000 or $0.01 per diluted share a year ago. Adjusted Net Income on non-GAAP measure was $26,193,000 or $0.76 per diluted share against $9,012,000 or $0.27 per diluted share a year ago. For the nine months, the company reported total revenues of $902,838,000, operating income of $105,866,000, income from continuing operations before provision for income taxes of $106,589,000, income from continuing operations of $66,756,000 or $1.97per diluted share, net income of $66,228,000 or $1.95 per diluted share against total revenues of $416,832,000, operating loss of $19,774,000, loss from continuing operations before benefit for income taxes of $26,249,000, loss from continuing operations of $18,951,000 or $0.56 per diluted share, net income of $19,309,000 or $0.57 per diluted share a year ago. Adjusted Net Income on non-GAAP measure was $63,594,000 or $1.87 per diluted share against adjusted net loss on non-GAAP measure of $6,634,000 or $0.20 per diluted share a year ago.